Tag Archives: BIO CEO

BIO CEO Company Snapshot: Conatus Pharmaceuticals

Conatus-Pharma

The Company Snapshots have returned for our next One-on-One Partnering event, the BIO CEO & Investor Conference, taking place in New York City this February. The companies that will be profiled in these snapshots will all be presenting at the event, and we hope this provides the opportunity to learn more about them, and catch up on what’s new. What is your company’s lead product or technology? Conatus’s lead product is emricasan, a first-in-class oral Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

#BIOBuyside Twitter Chat: What Do Biotech Investors Expect in 2014?

Dave Thomas

Is 2014 a good time to invest in biotech? How many biotech IPOs will there be? Which sectors will perform the best? To find out what investors think about these questions and more, BIO is conducting its annual Buy-side Investor Perception Survey and releasing the results at the 16th Annual BIO CEO & Investor Conference in New York, Monday Feb. 10. But as the results are coming in, BIO is hosting the #BIOBuyside Twitter chat Read More >

Inside BIO Industry Analysis  |  2 Comments  |  Email This Post
Tags: , , , , , , , , , ,

What’s In Store for Biotechs at this Year’s CEO & Investor Conference

CEO2014_blog copy

In just a few weeks, industry leaders will gather in New York for one of BIO’s largest and most successful events, the 16th Annual BIO CEO & Investor Conference. As we’ve seen at JPMorgan, the extraordinary performance of biotech equities for the past several years has generated a great deal of interest among investors to work with biotech companies to foster innovation in the coming year. This year’s event is shaping up to be even Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , ,

BIO White Paper Highlights Key Industry Legislation and its Impact on the Industry

Emerging-Companies115x76

Innovative biotech companies at all stages of the development process are working toward next generation technologies to heal, fuel, and feed the world. In an effort to highlight promising policy legislation and its impact on the biotech sector, BIO has authored the following white paper: The Future Policy Landscape for Emerging Biotechnology Companies. Many research-intensive companies rely on private investment to support their groundbreaking R&D. Therefore, favorable legislation such as the JOBS Act is essential Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Show Me the Money: Reimbursement in an ACA World

BIO CEO 2013

A panel at the BIO CEO & Investor Conference focused on reimbursement discussed value from a variety of perspectives and agreed that the landscape is shifting dramatically. The reimbursement roundtable featured payors, providers, and other stakeholders discussing Affordable Care Act (ACA) implementation and the wider reimbursement landscape. With many key provisions of the ACA slated to take effect in 2013 and beyond, the industry is facing sweeping changes to the managed care and reimbursement road map. Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,